SAR - AstraZeneca plc
January 26 2004 - 2:00AM
UK Regulatory
RNS Number:6106U
Capital Group Companies Inc
23 January 2004
FORM SAR 3
Lodge with Company Announcements Office and Newstrack, if appropriate, and the
Takeover Panel. A copy must also be sent to the company the shares of which are
acquired.
Date of disclosure - 23 January 2004
DISCLOSURE UNDER RULE 3 OF THE RULES GOVERNING SUBSTANTIAL ACQUISITIONS OF
SHARES ("SARs")
Date of acquisition 22 January 2004
Acquisition in AstraZeneca plc
(1) Class of voting shares Number of shares/rights over shares If rights over shares acquired, as
(e.g. ordinary shares) acquired opposed to the shares themselves,
specify nature of rights
Ordinary Shares 101,000 shares N/A
0 rights
(2) Resultant total holding of voting Resultant total holding of rights over Total percentage
shares (and % of total voting shares in shares (and % of total voting shares in
issue) issue)
254,143,676 (15.01%) 0 (0.00%) 15.01%
3) Party making disclosure The Capital Group Companies, Inc.
(4) (a) Name of person acquiring shares or rights over
shares and, if different, beneficial owner: The Capital Group Companies, Inc.
(b) Names of any other persons acting by
agreement or understanding (see SAR 5) N/A
Signed, for and on behalf of the party named in (3) above
_________________________________
(Also print name of signatory) Liliane Corzo
Telephone and extension number Contact Greg Dickinson (213) 615-0469
______________________________________
Note. Under SAR 5, the holdings of and acquisitions by persons acting by
agreement or understanding must be aggregated and treated as a holding of or
acquisition by one person. Note 3 on SAR 5 requires persons who must aggregate
holdings to disclose certain disposals.
For full details of the SARs disclosure requirements, see Rules 3 and 5 of the
SARs. If in doubt, contact the Panel on Takeovers and Mergers, Monitoring
Section, Tel. No: 020 7638 0129.
This information is provided by RNS
The company news service from the London Stock Exchange
END
SADPUUQAGUPCPWW